{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T04:28:06Z","timestamp":1785472086810,"version":"3.56.0"},"reference-count":20,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"vor","delay-in-days":1461,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000968","name":"American Heart Association","doi-asserted-by":"publisher","award":["858512"],"award-info":[{"award-number":["858512"]}],"id":[{"id":"10.13039\/100000968","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["K08 HL145138"],"award-info":[{"award-number":["K08 HL145138"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000738","name":"U.S. Department of Veterans Affairs","doi-asserted-by":"publisher","award":["lO1 BXOO4468"],"award-info":[{"award-number":["lO1 BXOO4468"]}],"id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["kidney-international.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1016\/j.kint.2021.12.006","type":"journal-article","created":{"date-parts":[[2021,12,22]],"date-time":"2021-12-22T20:12:23Z","timestamp":1640203943000},"page":"906-911","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Elamipretide treatment during pregnancy ameliorates the progression of polycystic kidney disease in maternal and neonatal mice with PKD1 mutations"],"prefix":"10.1016","volume":"101","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0703-0494","authenticated-orcid":false,"given":"Nastaran","family":"Daneshgar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peir-In","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renny S.","family":"Lan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"McKenna M.","family":"Horstmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsay","family":"Pack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gourav","family":"Bhardwaj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christie M.","family":"Penniman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian T.","family":"O\u2019Neill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dao-Fu","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.kint.2021.12.006_bib1","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1056\/NEJMoa1205511","article-title":"Tolvaptan in patients with autosomal dominant polycystic kidney disease","volume":"367","author":"Torres","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2021.12.006_bib2","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1053\/j.ajkd.2018.06.006","article-title":"Renal Disorders in pregnancy: core curriculum 2019","volume":"73","author":"Gonzalez Suarez","year":"2019","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kint.2021.12.006_bib3","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1681\/ASN.V551178","article-title":"Pregnancy outcome and its relationship to progression of renal failure in autosomal dominant polycystic kidney disease","volume":"5","author":"Chapman","year":"1994","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2021.12.006_bib4","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1681\/ASN.2014101051","article-title":"Comprehensive PKD1 and PKD2 mutation analysis in prenatal autosomal dominant polycystic kidney disease","volume":"27","author":"Audr\u00e9zet","year":"2016","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2021.12.006_bib5","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1681\/ASN.2010101080","article-title":"Mutations in multiple PKD genes may explain early and severe polycystic kidney disease","volume":"22","author":"Bergmann","year":"2011","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2021.12.006_bib6","doi-asserted-by":"crossref","first-page":"4257","DOI":"10.1172\/JCI64313","article-title":"Functional polycystin-1 dosage governs autosomal dominant polycystic kidney disease severity","volume":"122","author":"Hopp","year":"2012","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.kint.2021.12.006_bib7","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.ijgo.2006.03.025","article-title":"Oxidative stress markers and antioxidant levels in normal pregnancy and pre-eclampsia","volume":"94","author":"Sharma","year":"2006","journal-title":"Int J Gynaecol Obstet"},{"key":"10.1016\/j.kint.2021.12.006_bib8","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.2174\/0929866525666181101105209","article-title":"Stealth peptides target cellular powerhouses to fight rare and common age-related diseases","volume":"25","author":"Szeto","year":"2018","journal-title":"Protein Pept Lett"},{"key":"10.1016\/j.kint.2021.12.006_bib9","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1038\/clpt.2014.174","article-title":"Serendipity and the discovery of novel compounds that restore mitochondrial plasticity","volume":"96","author":"Szeto","year":"2014","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.kint.2021.12.006_bib10","doi-asserted-by":"crossref","first-page":"15363","DOI":"10.1073\/pnas.2002250117","article-title":"Mitochondrial protein interaction landscape of SS-31","volume":"117","author":"Chavez","year":"2020","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.kint.2021.12.006_bib11","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.jacc.2010.12.044","article-title":"Mitochondrial targeted antioxidant peptide ameliorates hypertensive cardiomyopathy","volume":"58","author":"Dai","year":"2011","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.kint.2021.12.006_bib12","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1161\/CIRCHEARTFAILURE.113.000406","article-title":"Global proteomics and pathway analysis of pressure-overload\u2013induced heart failure and its attenuation by mitochondrial-targeted peptides","volume":"6","author":"Dai","year":"2013","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.kint.2021.12.006_bib13","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1111\/bph.12461","article-title":"First-in-class cardiolipin-protective compound as a therapeutic agent to restore mitochondrial bioenergetics","volume":"171","author":"Szeto","year":"2014","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.kint.2021.12.006_bib14","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1038\/s42003-021-02730-w","article-title":"Metabolic derangement in polycystic kidney disease mouse models is ameliorated by mitochondrial-targeted antioxidants","volume":"4","author":"Daneshgar","year":"2021","journal-title":"Commun Biol"},{"key":"10.1016\/j.kint.2021.12.006_bib15","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.3389\/fphar.2019.01209","article-title":"Differential effects of the mitochondria-active tetrapeptide SS-31 (D-Arg-dimethylTyr-Lys-Phe-NH2) and its peptidase-targeted prodrugs in experimental acute kidney injury","volume":"10","author":"Wyss","year":"2019","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.kint.2021.12.006_bib16","doi-asserted-by":"crossref","first-page":"4138","DOI":"10.1074\/jbc.271.8.4138","article-title":"Activation of mitogen-activated protein kinase by H2O2: role in cell survival following oxidant injury","volume":"271","author":"Guyton","year":"1996","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.kint.2021.12.006_bib17","doi-asserted-by":"crossref","first-page":"807","DOI":"10.3109\/14767058.2015.1019458","article-title":"Pregnancy outcomes in autosomal dominant polycystic kidney disease: a case-control study","volume":"29","author":"Wu","year":"2016","journal-title":"J\u00a0Matern Fetal Neonatal Med"},{"key":"10.1016\/j.kint.2021.12.006_bib18","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1681\/ASN.2013121312","article-title":"Tolvaptan plus pasireotide shows enhanced efficacy in a PKD1 model","volume":"26","author":"Hopp","year":"2015","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2021.12.006_bib19","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1056\/NEJMoa1710030","article-title":"Tolvaptan in later-stage autosomal dominant polycystic kidney disease","volume":"377","author":"Torres","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"suppl 1","key":"10.1016\/j.kint.2021.12.006_bib20","doi-asserted-by":"crossref","first-page":"S83","DOI":"10.1007\/s10557-011-6357-x","article-title":"Nonclinical pharmacokinetics of a new nonpeptide V2 receptor antagonist, tolvaptan","volume":"25","author":"Furukawa","year":"2011","journal-title":"Cardiovasc Drugs Ther"}],"container-title":["Kidney International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253821011649?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253821011649?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T13:04:59Z","timestamp":1777640699000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0085253821011649"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":20,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["S0085253821011649"],"URL":"https:\/\/doi.org\/10.1016\/j.kint.2021.12.006","relation":{},"ISSN":["0085-2538"],"issn-type":[{"value":"0085-2538","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Elamipretide treatment during pregnancy ameliorates the progression of polycystic kidney disease in maternal and neonatal mice with PKD1 mutations","name":"articletitle","label":"Article Title"},{"value":"Kidney International","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.kint.2021.12.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 International Society of Nephrology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}